Senology Newsletter - May 8, 2012


Published on

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Senology Newsletter - May 8, 2012

  1. 1. Senology Newsletter Page 1 of 4 - Newsletter International Senologic and Oncologic  Scientific Community (ISOSC)  "Connecting specialists worldwide" Editor-in-Chief: Gian Paolo Andreoletti, MD Subscribe Unsubscribe Contact Back Issues Connecting Specialists Worldwide SENOLOGY GROUP on LiINKEDIN now has more than 1000 MEMBERS! JOIN US! Join us on LinkedIn, ResearchGate, Doctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Newspaper and follow our RSS feeds for real-time updates Literature Selection Kremer ME et al.: "Neglecting to screen women between the ages of 40 and 49 years with mammography: what is the impact on breast cancer diagnosis?", AJR Am J Roentgenol. 2012 May;198(5):1218-22 Kalager M et al.: "Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program", Ann Intern Med. 2012 Apr 3;156(7):491-9 Berg WA et al.: "Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk", JAMA. 2012 Apr 4;307 (13):1394-404 Vincent-Salomon A et al.: "High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients", Breast. 2012 Apr 22. [Epub ahead of print] Le Ray I et al.: "Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11years using propensity score matching", Eur J Cancer. 2012 Apr 16. [Epub ahead of print] Smith GL et al.: "Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer", JAMA. 2012 May 2;307(17):1827-37 Chen WW et al.: "The impact of diabetes mellitus on prognosis of early breast cancer in Asia", Oncologist. 2012 Apr;17(4):485-91 Ottini L et al.: "Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy", Breast Cancer Res Treat. 2012 Apr 18. [Epub ahead of print]file://C:Documents and SettingsutenteDesktopNewsletter_08May_2012.htm 08/05/2012
  2. 2. Senology Newsletter Page 2 of 4 Discussion - "Breast cancer screening with mammography " - Share your opinion on LinkedIn® Focus on - CLEOPATRA trial Baselga J et al.: "Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer", N Engl J Med 2012 Jan 12;366(2):109-19 - CLEOPATRA trial Calendar of Events 14th Milan Breast Cancer Conference, June 20-22, 2012, Milan, Italy Benign Breast Diseases, Breast Cancer and Basic Science, June 27-30, 2012, Naoussa, Macedonia, Greece 17th World Congress on Breast Diseases of the Senologic International Society, -SIS, October 10-13, 2012, Salvador, Bahia, Brazil 8th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC), November 15-17, 2012, Padova , Italy Fragments of History William S Halsted (New York, 1852-1922), "The results of radical operations for the cure of carcinoma of the breast", Ann Surg. July 1907:46(1):1-19": “The Operation - (...) It must be our endeavor to trace more definitely the routes travelled in the metastases to bone, particularly to the humerus, for it is even possible in case of involvement of this bone that amputation of the shoulder joint plus a proper removal of the soft parts might eradicate the disease. So, too, it is conceivable that ultimately, when our knowledge of the lymphatics traversed in cases of femur involvement becomes sufficiently exact, amputation at the hip joint may seem indicated" Literature Selection Smith AJ et al.: "Risk of cancer in first seven years after metal-on-metal hip replacement compared with other bearings and general population: linkage study between the National Joint Registry of England and Wales and hospital episode statistics", BMJ. 2012 Apr 3;344:e2383 Schlumberger M et al.: "Strategies of radioiodine ablation in patients with low-risk thyroid cancer", N Engl J Med. 2012 May 3;366(18):1663-73 Seghir Z et al.: "CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT", Thorax. 2012 Apr;67(4):296-301 Ho YF et al.: "Oral Bisphosphonates and Risk of Esophageal Cancer: A Dose-Intensity Analysis in a Nationwide Population", Cancer Epidemiol Biomarkers Prev. 2012 Apr 20. [Epub ahead of print] Broughton T et al.: "Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case- control study", BMC Gastroenterol. 2012 Apr 24;12(1):36. [Epub ahead of print] Turati F et al.: "Family history of liver cancer and hepatocellular carcinoma", Hepatology. 2012 May;55 (5):1416-25 Giannini E et al.: "Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis", Hepatology. 2012 Apr 26 [Epub ahead of print] Kang J et al.: "A DNA Repair Pathway-Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy", J Natl Cancer Inst. 2012 Apr 13. [Epub ahead of print] Tan HI et al.: "Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer", JAMA. 2012 Apr 18;307(15):1629-35 James ND et al.: "Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer", N Engl J Med. 2012 Apr 19;366(16):1477-88 Leongamornlert D et al.: "Germline BRCA1 mutations increase prostate cancer risk", Br J Cancer. 2012 Apr 19. doi: 10.1038/bjc.2012.146. [Epub ahead of print] Ahmed HU et al.: "Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study", Lancet Oncol. 2012 Apr 16. [Epub ahead of print]file://C:Documents and SettingsutenteDesktopNewsletter_08May_2012.htm 08/05/2012
  3. 3. Senology Newsletter Page 3 of 4 Comment "Metformin in the treatment of pancreatic cancer", Donghui Li, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA "Patients with pancreatic cancer often have a high prevalence (80%) of concurrent diabetes or impaired glucose tolerance, which are characterized by peripheral insulin resistance. Accumulating epidemiological and experimental evidence suggest metformin, the most commonly used antidiabetic drug, as an antitumor agent. In our retrospective study of 302 diabetic patients with pancreatic cancer, we observed that metformin users had 4 months longer overall survival time, 32% reduced risk of death, and about 2-fold higher 2-year survival rate than the nonmetformin group. These observations add supporting evidence for the antitumor activity of metformin. Findings from this retrospective investigation should prompt future research to test the hypothesis that metformin can be used as a supplemental therapy in the treatment of pancreatic cancer." (Comment on: Sadeghi N et al.: "Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer", Clin Cancer Res. 2012 Mar 31. [Epub ahead of print]) Literature Selection Svejme O et al.: "Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women", BJOG. 2012 Apr 25 [Epub ahead of print] Kotsopoulos j et al.: "Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers", Breast Cancer Res. 2012 ;14(2):R42. [Epub ahead of print] Knoppert DC et al.: "The Effect of Two Different Domperidone Dosages on Maternal Milk Production", J Hum Lact. 2012 May 3. [Epub ahead of print] collaborates with - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation. TalkAboutHealth Q&A of the month "In what cases should kidney cryoablation or radiofrequency ablation be considered to treat kidney cancer? " "Ablation is a new procedure for the treatment of kidney cancer that has even fewer complications than laparoscopic or robotic surgery and also requires a much shorter recovery time. Until recently the only treatment option for kidney tumors was to surgically remove them, either by removing the entire kidney (radical nephrectomy) or by removing just the tumor and surrounding region of kidney (partial nephrectomy). More recently, new technologies allow tumors to be destroyed, rendering them essentially harmless, without them actually being removed. In one form of ablation, radiofrequency energy is used to heat up and destroy the tumor. In another, known as cryoablation, the tumors are frozen to very low temperatures (-40 degrees Celsius!) and thereby destroyed. It is not clear which patients are the best candidates for ablation. In general, it seems the best candidates are patients with tumors less than 4cm in size. Also, there is a small risk that the patient will require a second treatment, which must be considered as well. Finally, the data on long-term outcomes are still being collected, so patients who want the most “tried and true” methods might opt for a different procedure" (Answer by Jaime Landman, Department of Urology,University of California, Irvine , CA, USA) Unsubscribefile://C:Documents and SettingsutenteDesktopNewsletter_08May_2012.htm 08/05/2012
  4. 4. Senology Newsletter Page 4 of 4       www.senology.orgfile://C:Documents and SettingsutenteDesktopNewsletter_08May_2012.htm 08/05/2012